These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15200155)

  • 41. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Confounders for kidney carcinogenesis in rodent cancer bioassays.
    Hard GC
    J Toxicol Pathol; 2022 Jan; 35(1):1-6. PubMed ID: 35221490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal artery stenosis and chronic ischemic nephropathy: epidemiology and diagnosis.
    Kendrick J; Chonchol M
    Adv Chronic Kidney Dis; 2008 Oct; 15(4):355-62. PubMed ID: 18805381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
    Negri AL
    J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary hypertension and nephropathy.
    Rosario RF; Wesson DE
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):130-4. PubMed ID: 16481878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duration of end-stage renal disease and kidney transplant outcome.
    Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
    Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interpreting incidence trends for treated end-stage renal disease: implications for evaluating disease control in Australia.
    Stewart JH; McCredie MR; Williams SM; McDonald SP
    Nephrology (Carlton); 2004 Aug; 9(4):238-46. PubMed ID: 15363056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis.
    Satoh S; Tsuchiya N; Habuchi T; Ishiyama T; Seimo K; Kato T
    J Urol; 2005 Nov; 174(5):1749-53. PubMed ID: 16217276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Critical evaluation of the cancer risk of dibromochloropropane (DBCP).
    Clark HA; Snedeker SM
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(2):215-60. PubMed ID: 16291528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Signs of active infection with Chlamydia pneumoniae in patients with coronary heart disease].
    Hrubá D; Roubalová K; Kraml P; Andĕl M
    Cas Lek Cesk; 2004; 143(12):830-5. PubMed ID: 15730214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating resistin concentrations in children depend on renal function.
    Nüsken KD; Kratzsch J; Wienholz V; Stöhr W; Rascher W; Dötsch J
    Nephrol Dial Transplant; 2006 Jan; 21(1):107-12. PubMed ID: 16144855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epithelium Lining Rat Renal Papilla: Nomenclature and Association with Chronic Progressive Nephropathy (CPN).
    Souza NP; Hard GC; Arnold LL; Foster KW; Pennington KL; Cohen SM
    Toxicol Pathol; 2018 Apr; 46(3):266-272. PubMed ID: 29504493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The incidence of chronic progressive nephrosis in young Sprague-Dawley rats from two different breeders.
    Palm M
    Lab Anim; 1998 Oct; 32(4):477-82. PubMed ID: 9807762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Commentary: the use of maximum tolerated dose in rodent carcinogenicity bioassays and its relevance to human risk assessment.
    Savolainen K
    Hum Exp Toxicol; 1997 Apr; 16(4):190-2. PubMed ID: 9154441
    [No Abstract]   [Full Text] [Related]  

  • 58. Solitons in the gauged CPN model.
    Cho YM; Kimm K
    Phys Rev D Part Fields; 1995 Dec; 52(12):7325-7327. PubMed ID: 10019272
    [No Abstract]   [Full Text] [Related]  

  • 59. Solitons in the supersymmetric CPN-1 model.
    Köberle R; Kurak V
    Phys Rev D Part Fields; 1987 Jul; 36(2):627-628. PubMed ID: 9958209
    [No Abstract]   [Full Text] [Related]  

  • 60. theta -term renormalization in (2+1)-dimensional CPN-1 model with a theta term.
    Park SH
    Phys Rev D Part Fields; 1992 May; 45(10):R3332-R3335. PubMed ID: 10014298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.